RxSight’s FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from contemporary toric IOLs, were accepted for publication in the ...

RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was ...

RxSight’s blended fair value estimate has edged down to US$10.17 from US$10.39, reflecting a modest recalibration in the latest round of research updates. Analysts are largely sticking with neutral ...

In the last three months, 11 analysts have published ratings on RxSight (NASDAQ:RXST), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 22, 2025 deadline to participate as a lead plaintiff in the securities fraud class action ...

Analysts' ratings for RxSight (NASDAQ:RXST) over the last quarter vary from bullish to bearish, as provided by 3 analysts. The table below provides a concise overview of recent ratings by analysts, ...

We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where RxSight, Inc. (NASDAQ:RXST) stands against other most ...

ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, ...

On November 29, 2024, RxSight, Inc. filed a notice of data breach with the Attorney General of Montana after discovering that an unauthorized party accessed an employee’s email account. In this notice ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 22, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors ...